In last trading session, Acadia Pharmaceuticals Inc (NASDAQ:ACAD) saw 2.21 million shares changing hands with its beta currently measuring 0.40. Company’s recent per share price level of $15.82 trading at $0.55 or 3.60% at ring of the bell on the day assigns it a market valuation of $2.61B. That closing price of ACAD’s stock is at a discount of -114.85% from its 52-week high price of $33.99 and is indicating a premium of 7.4% from its 52-week low price of $14.65. Taking a look at company’s average trading volume volume of 1.92 million if we extend that period to 3-months.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) trade information
Upright in the green during last session for gaining 3.60%, in the last five days ACAD remained trading in the green while hitting it’s week-highest on Wednesday, 05/22/24 when the stock touched $15.82 price level, adding 1.12% to its value on the day. Acadia Pharmaceuticals Inc’s shares saw a change of -49.47% in year-to-date performance and have moved 4.63% in past 5-day. Acadia Pharmaceuticals Inc (NASDAQ:ACAD) showed a performance of -5.50% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Acadia Pharmaceuticals Inc (ACAD) estimates and forecasts
Statistics highlight that Acadia Pharmaceuticals Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -30.98% of value to its shares in past 6 months, showing an annual growth rate of 254.05% while that of industry is 15.20. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 28.03% during past 5 years.
ACAD Dividends
Acadia Pharmaceuticals Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
